These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. Penson RT; Ambrosio AJ; Whalen CA; Krasner CN; Konstantinopoulos PA; Bradley C; Matulonis UA; Birrer MJ Oncologist; 2023 Mar; 28(3):252-257. PubMed ID: 36718018 [TBL] [Abstract][Full Text] [Related]
7. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072 [TBL] [Abstract][Full Text] [Related]
8. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Hirte H; Oza A; Swenerton K; Ellard SL; Grimshaw R; Fisher B; Tsao M; Seymour L Gynecol Oncol; 2010 Sep; 118(3):308-12. PubMed ID: 20646751 [TBL] [Abstract][Full Text] [Related]
10. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768 [TBL] [Abstract][Full Text] [Related]
11. Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. Wu X; Zhu J; Wang J; Lin Z; Yin R; Sun W; Zhou Q; Zhang S; Wang D; Shi H; Gao Y; Huang Y; Li G; Wang X; Cheng Y; Lou G; Gao Q; Wang L; Du X; Pan M; Mu X; Li L; Li M; Mu S; Kong B Clin Cancer Res; 2022 Feb; 28(4):653-661. PubMed ID: 34844979 [TBL] [Abstract][Full Text] [Related]
12. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565 [TBL] [Abstract][Full Text] [Related]
13. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118 [TBL] [Abstract][Full Text] [Related]
14. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study. Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635 [TBL] [Abstract][Full Text] [Related]
15. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline Poveda AM; Davidson R; Blakeley C; Milner A Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers. Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515 [TBL] [Abstract][Full Text] [Related]
17. ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer. Kuroda Y; Chiyoda T; Kawaida M; Nakamura K; Aimono E; Yoshimura T; Takahashi M; Saotome K; Yoshihama T; Iwasa N; Sakai K; Yamagami W; Nishihara H; Aoki D Gynecol Oncol; 2021 Sep; 162(3):679-685. PubMed ID: 34272091 [TBL] [Abstract][Full Text] [Related]
18. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273 [TBL] [Abstract][Full Text] [Related]
19. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572 [TBL] [Abstract][Full Text] [Related]
20. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]